Active Implants

Minimally Invasive Orthopedic Implants

Health Tech & Life Sciences
Non Active, Dec 2023 ceased to operate

Company Overview

Snapshot

Founded in January 2004 by Sandra R. (Lewkowski) Steinberg and Amiram Steinberg, Active Implants operated with 11–50 employees. The company raised a total of $101.13 million across 7 funding rounds from 4 investors. In September 2019, Active Implants received FDA Breakthrough Device Designation for its NUsurface Meniscus Implant.

Business overview

Active Implants develops orthopedic implant solutions designed to complement the natural biomechanics of the musculoskeletal system, enabling patients to maintain an active lifestyle. The company's core product, the NUsurface meniscus implant, is designed for the treatment of meniscal-deficient knees through a minimally invasive procedure, aiming for bone conservation. Additionally, its TriboFit hip system, which received a CE mark in 2006, consists of acetabular components for hip joint reconstruction applications. Active Implants operates within the Health Tech & Life Sciences sector, focusing on medical devices and orthopedics, serving markets in Spain, Portugal, Italy, and the Netherlands.

Strategic signal

In September 2019, Active Implants received FDA Breakthrough Device Designation for its NUsurface Meniscus Implant. This designation highlights the potential of the NUsurface implant to provide a more effective treatment for meniscal-deficient knees, signaling strong regulatory validation and a pathway for accelerated development and review in the US market. This is a significant indicator for investors of the company's innovation and potential impact in orthopedic surgery.

Company Intelligence Q&A

What is the status of Active Implants?
Active Implants is Non Active and ceased to operate in December 2023.
When was Active Implants founded?
Active Implants was founded in January 2004.
What significant regulatory milestone did Active Implants achieve for its NUsurface Meniscus Implant?
In September 2019, Active Implants received FDA Breakthrough Device Designation for its NUsurface Meniscus Implant.
What was the total capital raised by Active Implants?
Active Implants raised a total of $101.13 million across 7 funding rounds.
What was a key development regarding the NUsurface trial enrollment?
In July 2018, Active Implants completed enrollment for its NUsurface trial.

External links